1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,119 | 0,167 | 24.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.04. | Cantargia Publishes Annual Report 2024 | 219 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced that the annual report for 2024 has been published. The... ► Artikel lesen | |
| 11.04. | Notice of Annual General Meeting in Cantargia AB | 217 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Thursday, 15 May 2025, at 15.00 CEST at Ideon... ► Artikel lesen | |
| 01.04. | Cantargia appoints Morten Lind Jensen as Chief Medical Officer | 193 | ACCESS Newswire | LUNDE, SE / ACCESS Newswire / April 1, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced the appointment of Morten Lind Jensen, MD, PhD, as Chief... ► Artikel lesen | |
| 25.03. | Cantargia Publishes An Abstract On Parallel Anti-Tumor Activity And Reduction Of Chemotherapy-Induced Neuropathy With Nadunolimab | 428 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA)Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR clinical... ► Artikel lesen | |
| 25.03. | Cantargia Presents Promising Preclinical Results on a Novel IL1RAP-Targeting Antibody-Drug Conjugate at AACR 2025 | 294 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced an upcoming presentation of preclinical data on the development... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 13.03. | Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference | 323 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 13, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that members of Cantargia's management will participate... ► Artikel lesen | |
| 12.03. | Cantargia (OMX: CANTA) enrols first patient in leukaemia study | 270 | Edison Investment Research | Cantargia has confirmed that the first patient has been in enrolled in the study assessing nadunolimab in leukaemia. More specifically, this is an investigator-initiated, open-label, Phase Ib/IIa clinical... ► Artikel lesen | |
| 12.03. | First Patient Enrolled in Cantargia's Leukemia Study with nadunolimab | 399 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 12, 2025 / Cantargia (STO:CANTA)Open label study in forty AML and MDS patientsStudy financed by the US Department of DefenseCantargia (Cantargia AB; Nasdaq Stockholm:CANTA)... ► Artikel lesen | |
| 10.03. | Cantargia (OMX: CANTA) breast cancer study fully recruited | 281 | Edison Investment Research | Cantargia has announced that it has completed recruiting patients (n=102) for the randomised Phase II TRIFOUR trial, which is evaluating nadunolimab in combination with platinum-based chemotherapy,... ► Artikel lesen | |
| 10.03. | Cantargia's TRIFOUR Phase 2 Study Investigating Nadunolimab in Triple Negative Breast Cancer Fully Recruited | 243 | ACCESS Newswire | TRIFOUR is Cantargia's first randomized, controlled study of nadunolimabFirst preliminary efficacy results expected mid-2025 LUND, SWEDEN / ACCESS Newswire / March 10, 2025 / Cantargia (Cantargia AB)... ► Artikel lesen | |
| 06.03. | Cantargia to Participate at H.C. Wainwright's Annual Autoimmune & Inflammatory Virtual Conference | 211 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 6, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate at the... ► Artikel lesen | |
| 05.03. | Cantargia (OMX: CANTA) reports positive CAN10 update | 284 | Edison Investment Research | Cantargia has reported encouraging pharmacokinetic data from the first cohort in the multiple ascending dose portion of the CAN10 study. Importantly, the data align with the single dose portion of the... ► Artikel lesen | |
| 05.03. | Cantargia Reports Promising CAN10 Phase 1 Data From First Multiple Dose Cohort, and FDA and Key Opinion Leader Feedback | 250 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 5, 2025 / Cantargia (STO:CANTA)Promising multiple dose PK data continue to support 4-weekly dosingFDA advice received supporting phase 2 design in HSStrong Key Opinion... ► Artikel lesen | |
| 21.02. | Cantargia Publishes Full Year Report for 2024 | 276 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / February 21, 2025 / Cantargia (STO:CANTA) Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) full year report for 2024 is now available on the company's web... ► Artikel lesen | |
| 19.02. | Cantargia to Participate in Leerink Partners Global Healthcare Conference | 249 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 19, 2025 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargia's management will participate in one-on-one meetings... ► Artikel lesen | |
| 13.02. | Invitation to Presentation of Cantargia's Year-End Report 2024 | 192 | ACCESS Newswire | LUND, SE / ACCESSWIRE / February 13, 2025 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) invites investors, analysts and the press to a presentation of the interim October... ► Artikel lesen | |
| 05.02. | Cantargia Announces Management Changes | 334 | ACCESS Newswire | Göran Forsberg, CEO, steps downDamian Marron, Board Director, to assume role of Interim CEORecruitment process for new permanent CEO underway LUND, SWEDEN / ACCESS Newswire / February 5, 2025 / Cantargia... ► Artikel lesen | |
| 31.01. | Cantargia Announces Changes in Number of Shares and Votes | 258 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / January 31, 2025 / Cantargia AB's (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm:CANTA) today announced that the number of shares and votes in Cantargia AB... ► Artikel lesen | |
| 18.12.24 | Cantargia Publishes Strong Preclinical Effects and Clinical Monotherapy Results on Nadunolimab in Pancreatic Cancer in Journal for Immunotherapy of Cancer | 352 | ACCESS Newswire | LUND, SE / ACCESSWIRE / December 18, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of preclinical and clinical results using the IL1RAP... ► Artikel lesen | |
| 11.12.24 | Cantargia and GEICAM Present Updated Phase 1 Clinical Data and New Translational Results on Nadunolimab Treatment in Advanced Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium | 411 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / December 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported updated results from the phase 1b study in 15 advanced triple negative... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 102,20 | +0,79 % | BioNTech Aktie: Leichte Erholung im Fokus | BioNTech zeigt technische Erholungssignale trotz schwieriger Bewertung. Analysten halten an Kaufempfehlungen fest - wohin steuert die Aktie? Die BioNTech-Aktie zeigt nach turbulenten Wochen erste Anzeichen... ► Artikel lesen | |
| EVOTEC | 7,344 | +1,75 % | Evotec: Neue Strategie und starkes Ergebnis im vierten Quartal! | ||
| QIAGEN | 37,610 | +0,17 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 524,20 | -0,38 % | Regeneron Pharma Partners With FujiFilm Diosynth To Boost Capacity At $3 Bln Investment | WASHINGTON (dpa-AFX) - Regeneron Pharma, Inc. (REGN), a biotechnology company, on Tuesday announced a major expansion of its manufacturing capacity through a new agreement with FujiFilm Diosynth... ► Artikel lesen | |
| BRAIN BIOTECH | 2,370 | +1,28 % | EQS-News: BRAIN Biotech AG: Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Hauptversammlung
Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG
18.03.2025 / 16:45 CET/CEST
Für... ► Artikel lesen | |
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal | San Antonio, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,939 | -0,11 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 23.04.2025 / 15:24 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,056 | 0,00 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CSL | 137,80 | +0,38 % | CSL Behring und GKV-Spitzenverband einigen sich auf Erstattungspreis für HEMGENIX® - Europas erste Gentherapie für Hämophilie B | Marburg (ots) - CSL Behring und der GKV-Spitzenverband haben die Verhandlungen über den Erstattungspreis von HEMGENIX® erfolgreich abgeschlossen. Damit steht die erste in Europa zugelassene Gentherapie... ► Artikel lesen | |
| MANNKIND | 4,089 | -0,39 % | MannKind Corp. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for MannKind Corp. (MNKD):Earnings: $7.42 million in Q4 vs. $1.40 million in the same period last year.
EPS: $0.03 in Q4 vs. $0.00... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,478 | +0,41 % | Oxford Nanopore Technologies: Breakthrough algorithm enables partially phased, near telomere-to-telomere assembly using standard Oxford Nanopore Simplex reads | New hifiasm-ONT assembly method delivers high-quality, cost-efficient near T2T assemblies using standard Oxford Nanopore Simplex reads, broadening access to comprehensive genome assemblies across... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,866 | -1,01 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today announced that... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,236 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Provides Q4 and Full Year 2024 Business Update | TECELRA® launch momentum accelerating - 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission... ► Artikel lesen | |
| CODEXIS | 2,000 | -0,79 % | Codexis Aktie: Folgenschwere Entwicklung? | Die Codexis Aktie verzeichnete am 22. März 2025 einen leichten Anstieg von 1,94% und schloss bei 2,36 EUR. Diese positive Entwicklung kommt nach einem schwierigen Monat, in dem das Biotechnologieunternehmen... ► Artikel lesen | |
| TELO GENOMICS | 0,053 | 0,00 % | Telo Genomics Corp.: Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025 | Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human... ► Artikel lesen |
Das Unternehmen CANTARGIA AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,120 Euro und damit +5,28 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.
